Objectives: We investigated the effect of isoflavone on postmenopausal symptoms, urinary isoflavone excretion, serum lipid profiles and bone markers to know the effect of isoflavone in postmenopausal women. Methods: 30 postmenopausal women took part in this study. They are divided into 3 subgroups according to the dose of isoflavone supplementation of 100 mg/day, 150 mg/day, and 200 mg/day. Isoflavones were consumed for 6 months. Fasting serum total cholesterol, triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL) cholesterol lenel, lipoprotein-a, osteocalcin, and urinary deoxypyridinoline levels were measured initially and 6 months after each isoflavone supplementations. Result: The urinary isoflavone excretion was dose dependent in postmenopausal women and average 24-hr urinary recoveries of daidzein and genistein were approximately 15% and 7% respectively. isoflavone may not affect the serum total cholesterol, TG, LDL cholesterol, and lipoprotein-a levels. but isoflavone increase the HDL cholesterol level in each supplementation, especially increase significantly in 150 mg from 48.6±8.2 mg/dl to 57.3±9.9 mg/dl. Isoflavone decrease the bone marker, but it is not significant statistically. Conclusion: We suggest the isoflavone may beneficial effect on lipid profiles especially increasing serum HDL cholesterol level.